AR065504A1 - Terapia combinada para el tratamiento de la hepatitis b cronica. uso. - Google Patents

Terapia combinada para el tratamiento de la hepatitis b cronica. uso.

Info

Publication number
AR065504A1
AR065504A1 ARP080100816A ARP080100816A AR065504A1 AR 065504 A1 AR065504 A1 AR 065504A1 AR P080100816 A ARP080100816 A AR P080100816A AR P080100816 A ARP080100816 A AR P080100816A AR 065504 A1 AR065504 A1 AR 065504A1
Authority
AR
Argentina
Prior art keywords
antiviral
treatment
association
drugs
hbv
Prior art date
Application number
ARP080100816A
Other languages
English (en)
Inventor
Rubido Julio Cesar Aguilar
Arias Eduardo Penton
Gonzalez Verena Lucila Muzio
Laurent Guillot
Gomez Raimundo Ubieta
Blanco Sonia Gonzalez
Martinez Luis Saturnino Herrera
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR065504A1 publication Critical patent/AR065504A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Uso de un inmunopreparado de naturaleza proteoliposomal que comprende a la proteína ôSö del virus de la hepatitis B (VHB) obtenida mediante inmunoafinidad para la preparacion de una composicion farmacéutica para el tratamiento de pacientes conhepatitis B cronica mediante un método que consiste en la administracion de dicho inmunopreparado en asociacion con una cantidad efectiva de un antiviral con actividad inhibidora de la replicacion del VHB, caracterizada en que el tratamientoantiviral se realiza en un tiempo igual o inferior a los 6 meses. La administracion de ambos fármacos en asociacion resulta en niveles de eficacia superiores a los obtenidos con los tratamientos convencionales, en cuanto a respuesta terapéuticaclínicamente significativa, caracterizada por una disminucion de la carga viral por debajo de 10.000 copias por mL de suero, normalizacion de las transaminasas y mejoría de los índices de dano histologico. Producto del tiempo en que se administranambos fármacos en asociacion, se elimina la aparicion de mutantes de escape a los antivirales. Reivindicacion 11: Un método para incrementar los niveles de anticuerpos en pacientes de HBC mediante la administracion de un inmunopreparadoproteoliposomal que comprende la proteína ôSö de la envoltura del VHB, obtenida mediante inmunoafinidad, en asociacion con un antiviral perteneciente al grupo de inhibidores de la polimerasa viral utilizados para el tratamiento de la HBC en unperíodo igual o inferior a los 6 meses de tratamiento antiviral.
ARP080100816A 2007-02-28 2008-02-27 Terapia combinada para el tratamiento de la hepatitis b cronica. uso. AR065504A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20070050 2007-02-28

Publications (1)

Publication Number Publication Date
AR065504A1 true AR065504A1 (es) 2009-06-10

Family

ID=39564658

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100816A AR065504A1 (es) 2007-02-28 2008-02-27 Terapia combinada para el tratamiento de la hepatitis b cronica. uso.

Country Status (2)

Country Link
AR (1) AR065504A1 (es)
WO (1) WO2008104133A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200102024T2 (tr) * 1999-01-12 2001-12-21 Smithkline Beecham Biologicals S.A. Yeni tedavi.
CN1364644A (zh) * 2002-02-05 2002-08-21 北京多米诺医药研究所 免疫性脂质体治疗性乙肝疫苗及其制备方法

Also Published As

Publication number Publication date
WO2008104133A1 (es) 2008-09-04

Similar Documents

Publication Publication Date Title
Perrillo Treatment of chronic hepatitis B with interferon: experience in western countries
Theiss et al. Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction
CN1094642A (zh) 治疗组合物
WO2016173486A1 (zh) 曲美他嗪在制备防治肝病的药物中的用途
Yuen et al. RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients
KR20050044587A (ko) Ｂ형 간염 바이러스 감염 치료용 포스포네이트뉴클레오타이드 유사체의 용도
RU2012136824A (ru) Способы лечения вирусной инфекции гепатита с
Lawitz et al. All‐oral therapy with nucleotide inhibitors sofosbuvir and GS‐0938 for 14 days in treatment‐naive genotype 1 hepatitis C (NUCLEAR)
MX2010013522A (es) Uso de telaprevir en combinacion con interferon pegilado y ribavirina para tratar el virus de la hepatitis c.
Chang et al. Combined effects of mesenchymal stem cells carrying cytosine deaminase gene with 5-fluorocytosine and temozolomide in orthotopic glioma model
RU2008151516A (ru) СПОСОБ УВЕЛИЧЕНИЯ БИОЛОГИЧЕСКОЙ АКТИВНОСТИ ОЧИЩЕННОГО БЕЛКА HspE7
Baweja et al. Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod
AR065504A1 (es) Terapia combinada para el tratamiento de la hepatitis b cronica. uso.
Cusack et al. Successful treatment of florid cutaneous warts with intravenous cidofovir in an 11‐year‐old girl
RU2013120345A (ru) Новые способы лечения инфекции, вызванной вирусом гепатита с
JP2019535830A5 (es)
Sho et al. Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C
CN114796233A (zh) 积雪草酸在制备乙型肝炎治疗药物中的用途
US9084758B2 (en) Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereof
CN106619619A (zh) 化合物hubin‑1在制备肝脏炎症性疾病预防和/或治疗药物中的用途
US9345733B1 (en) Supplement composition for supporting telomere maintenance and protection and method of use
Hosseinnezhad et al. Acute renal failure, thrombocytopenia, and elevated liver enzymes after concurrent abuse of alcohol and cocaine
Bao-En Ademetionine 1, 4-Butanedisulphonate vs Traditional Chinese medicine for the treatment of acute viral hepatitis with hepatocellular jaundice
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
MD3121F1 (en) Method of viral hepatitis B prophylaxis

Legal Events

Date Code Title Description
FB Suspension of granting procedure